---
title: "SGMO.US (SGMO.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SGMO.US/news.md"
symbol: "SGMO.US"
name: "SGMO.US"
parent: "https://longbridge.com/en/quote/SGMO.US.md"
datetime: "2026-03-05T13:39:49.782Z"
locales:
  - [en](https://longbridge.com/en/quote/SGMO.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SGMO.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SGMO.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/SGMO.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/SGMO.US/news.md)


# SGMO.US (SGMO.US) — Related News

### [Balanced Risk/Reward at uniQure: Early Promise for AMT-191 Offset by Regulatory and Competitive Uncertainty Around AMT-130](https://longbridge.com/en/news/275159699.md)
*2026-02-06T17:25:23.000Z*
> William Blair analyst Sami Corwin maintains a Hold rating on uniQure (QURE) stock, citing a balanced risk/reward scenari

### [Pre-market hot trades in US stocks: Atlas Critical Minerals up 15.21% pre-market; Sangamo Therap up 10.26% pre-market](https://longbridge.com/en/news/274789520.md)
*2026-02-04T09:42:39.000Z*
> Atlas Critical Minerals pre-market up 15.21%; Sangamo Therap pre-market up 10.26%; Park Ha Biological Tech pre-market up

### [FDA prüft Zulassungsantrag für Sangamos Gentherapie bei Fabry-Krankheit](https://longbridge.com/en/news/274710426.md)
*2026-02-03T21:08:56.000Z*
> Sangamo Therapeutics Inc. has initiated a rolling submission of a Biologics License Application (BLA) to the FDA for its

### [Sangamo Therapeutics reveals detailed data from registrational STAAR study on Fabry Disease at WORLDSymposium 2026.](https://longbridge.com/en/news/274713477.md)
*2026-02-03T21:07:07.000Z*
> Sangamo Therapeutics recently unveiled in-depth information from the registrational STAAR study on Fabry disease at the 

### [12 Health Care Stocks Moving In Tuesday's Intraday Session](https://longbridge.com/en/news/274690209.md)
*2026-02-03T17:05:44.000Z*
> Bristol-Myers Squibb (CELGR) shares surged 31.8% to $0.1, while Liminatus Pharma (LIMN) rose 26.26% to $0.72. Adlai Nort

### [BUZZ-Sangamo Therapeutics slides after $25 million stock sale](https://longbridge.com/en/news/274672477.md)
*2026-02-03T14:27:11.000Z*
> Shares of genomic medicine firm Sangamo Therapeuticsslide 19% to $0.46 premarketSGMO announces pricing of $25 million st

### [Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering | SGMO Stock News](https://longbridge.com/en/news/274671212.md)
*2026-02-03T06:10:00.000Z*
> Sangamo Therapeutics, Inc. has announced the pricing of a $25 million underwritten offering, which includes 35,190,292 s